Rockefeller Capital Management
MBRX icon

Rockefeller Capital Management’s Moleculin Biotech MBRX Stock Holding History

Rockefeller Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8K Buy
750
+529
+239% +$27K ﹤0.01% 3449
2026
Q1 		$10.1K Buy
221
+210
+1,909% +$13.9K ﹤0.01% 3990
2025
Q4 		$722 Sell
11
-18
-62% -$3.35K ﹤0.01% 4492
2025
Q3 		$7.69K Buy
+29
New +$7.83K ﹤0.01% 3743
2023
Q1 		– Hold
0
– -$1K – 3108
2022
Q4 		– Hold
0
– – – 3711
2022
Q3 		– Hold
0
– – – 3746
2022
Q2 		– Hold
0
– – – 3804
2022
Q1 		– Hold
0
– – – 3424
2021
Q4 		– Hold
0
– – – 3278
2021
Q3 		– Hold
0
– – – 2998
2021
Q2 		– Hold
0
– – – 2778
2021
Q1 		– Hold
0
– – – 2514
2019
Q4 		– Hold
0
– -$3K – 2144
2019
Q3 		– Hold
0
– – – 1731

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EFG International
EFG International Zurich $5.46B AUM

Rockefeller Capital Management's MBRX Position: Q2 2026 in Review

Rockefeller Capital Management increased its Moleculin Biotech (MBRX) stake by 239% in Q2 2026, buying an estimated $27K and bringing the position to 750 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3449.

Rockefeller Capital Management first reported a position in MBRX in Q3 2025 and has held it in 4 quarters since. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Rockefeller Capital Management held 750 shares of Moleculin Biotech worth $41.8K as of Q2 2026.
  • Rockefeller Capital Management bought 529 Moleculin Biotech shares in Q2 2026, an estimated $27K.
  • Moleculin Biotech made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3449 holding.
  • Rockefeller Capital Management first reported a position in Moleculin Biotech in Q3 2025 and has held it in 4 quarters since.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.